Stroke, IschemicL-HARPNCT05132465
Liverpool-Heart and BRain Project Stroke Cohort
An observational study of Stroke, Ischemic and Transient Ischemic Attack, run by University of Liverpool at 1 site in United Kingdom.
Trial summary
What research question is being addressed? Can improve the prediction of adverse outcomes be improved for people following a stroke to optimise their treatment and care? How is it of relevance and importance to patients and public? Following a stroke, people are at a higher risk of developing certain conditions… Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Stroke, Ischemic, Transient Ischemic Attack
- How many people
- 1,655 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 12 Oct 2021to 10 Jun 2024
- How long will I take part?
- 12 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients from participating hospitals with a recent ischaemic stroke confirmed by stroke physician or transient ischaemic attack confirmed by MRI are eligible unless they are received palliative or end-of-life care. This study aims to be as inclusive as possible with recruitment and provide methods for advice to be sought from a personal consultee (relative/friend/carer) where informed consent is not possible in line with the Mental Capacity Act 2005.
Who may be able to join
- ≥18 years old
- Current in-patient at a participating hospital the time of baseline data collection for recent ischaemic stroke confirmed by stroke physician or transient ischaemic attack confirmed by magnetic resonance imaging (MRI)
Who cannot join
- Inability to provide informed consent and no personal consultee available or personal consultee does not think the person would want to participate
- Receiving palliative or end-of-life care
Trial locations and contacts
1 site in 1 country.
About this study
What research question is being addressed?
Can improve the prediction of adverse outcomes be improved for people following a stroke to optimise their treatment and care?
Read more
How is it of relevance and importance to patients and public?
Following a stroke, people are at a higher risk of developing certain conditions including heart failure, another stroke and atrial fibrillation, a type of irregular heart rhythm. In the proposed study, the investigators will look at factors which may increase a person's risk of such conditions following stroke. From this, the investigators will determine if risk scores for these conditions can be improved for people post-stroke. This could help doctors decide what treatments are best.
Who would be eligible?
All adults at participating hospitals who have had an ischaemic stroke (where the stroke is caused by loss of blood flow to the brain) or a transient ischaemic attack ('mini-stroke') confirmed by a stroke doctor. All patients will be asked to take part in the study, or their family members may be asked to provide advice on their behalf if the patient is unable to.
Where is the study being conducted?
At participating hospitals in England and Wales.
What will the participants undergo?
At the time of stroke, patients have a lot of information collected about their health, the investigators will copy information from patient's medical records about their health after they agree to take part in the study. Patients or their family members will also be asked to complete some additional brief questionnaires about their quality of life, wellbeing and fatigue. Some questionnaires such as for cognitive function are already collected for patients following a stroke, but where this information has not been collected, it will be collected for the study. The investigators will ask the patients if they can be contacted in 12-months to repeat the questionnaires and information collected about their health.
Read the detailed description
Study purpose and design.
People with prior stroke are at a high-risk of incident adverse cardiovascular outcomes including heart failure, atrial fibrillation (AF), recurrent stroke and vascular cognitive impairment and dementia. However, there is a need to clarify the underlying risk factors for these outcomes specific to post-stroke populations. Extensive research has been conducted to identify individuals at high-risk of cardiovascular disease through the development of risk prediction models. This has led to the incorporation of risk models for cardiovascular disease into guidelines for clinical practice with an aim to improve patient-centred care and decision-making. Risk factors frequently incorporated in such models include age, male sex, hypertension, cholesterol, smoking, and diabetes mellitus. Although some risk prediction models have examined cardiovascular outcomes such as AF in people post-stroke, further research is needed to refine these models and make recommendations for implementation to clinical practice. Identifying precise risk prediction models for cardiovascular disease and cardiovascular-related complications in people post-stroke is needed to target screening for conditions (such as AF) and develop targeted intervention strategies specific to this population.
Quality assurance plan
Pseudo-anonymised data using the unique, non-identifiable participant ID will be collected in an electronic case report form using Research Electronic Data Capture (REDCap; https://www.project-redcap.org). The data entered in to REDCap for the first 20 patients recruited at each site will be remotely checked for completeness. The data entered onto REDCap will be checked against electronic medical records and paper questionnaires at selected sites.
Data checks
The data fields in REDCap have been set with predefined rules for range or consistency and error messages will display when these rules are violated.
Sample size assessment
As one of the main aims of the study is to examine post-stroke risk prediction models for AF, this will be used to determine the sample size. Post-stroke prevalence of AF has been estimated at approximately 24%. Based on the 24% and with a conservative estimate of 15 cases required per variable in the model, 195 cases would be appropriate for a 13-variable model, which is the maximum number of variables included in previous AF prediction models. Therefore, 815 participants would give approximately 195 patients who develop AF required for the model. The study aims to recruit these participants and 20% extra to account for potential loss to follow-up, resulting in a minimum of 978 participants.
Statistical analysis plan
All data collected will be quantitative. Data will be analysed by members of the research team at the Liverpool Centre for Cardiovascular Science. Cox proportional hazard models adjusted for potential confounding factors will be used to examine associations between risk factors and cardiovascular outcomes and mortality. Risk models identified in previous studies for AF and cardiovascular-related outcomes including cardiovascular disease, physical function, cognitive impairment and dementia, quality-of-life, and all-cause and cardiovascular mortality will be examined in the L-HARP stroke cohort. Receiver operating characteristic curves will be constructed, and Harrell C indexes (i.e. area under the curve) will be estimated as a measure of model performance and compared using the DeLong test.
In addition to traditional epidemiological approaches to risk prediction modelling, machine learning methodologies will also be examined. Machine learning has been shown to produce comparable results to traditional cardiovascular disease risk prediction scores, but with advantages such as examining all available data in an unbiased approach which could lead to the discovery of new relationships among data. As the sample is not very large, traditional machine learning techniques including k-Nearest Neighbours, random forest, and decision tree will be utilised rather than deep learning techniques which are usually applied to very large datasets. A subset of the data will be used for the training of the model and the rest of the data will be used for the evaluation of the model. The model derived from machine learning will be compared to risk prediction models described in previous studies. The accuracy, specificity, sensitivity, positive predictive value and negative predictive value of the models will be compared.
- Conditions
- Stroke, Ischemic, Transient Ischemic Attack
- Keywords
- stroke, observational study
- Medical subject headings
- Ischemic Stroke, Ischemic Attack, Transient, Stroke
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants with incident stroke, transient ischaemic attack, atrial fibrillation, myocardial infarction and heart failure
Incident stroke, transient ischaemic attack, atrial fibrillation, myocardial infarction and heart failure
Measured: 12 months
Mortality
All-cause mortality and mortality from cardiovascular causes
Measured: 12 months
Number of participants with incident cognitive impairment
Cognitive impairment determined from Montreal Cognitive Assessment (MoCA) test results
Measured: 12 months
Number of participants with incident dementia
Dementia determined from clinical diagnosis
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Nov 2021
- Study start12 Oct 2021
- Primary completion10 Jun 2024
- Study completion10 Jun 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Stroke, IschemicStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,655 participants (actual)
- Target duration
- 12 Months
Sponsor and investigators
- Lead sponsor
- University of Liverpool
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Stephanie L Harrison, PhD, Principal investigator, University of Liverpool
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05132465
- Sponsor's protocol ID
- UoL001512
- Acronym
- L-HARP
- Status last verified
- Mar 2024
- First submitted
- 12 Nov 2021
- Last updated
- 21 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Harrison SL, Lane DA, Buckley BJR, Chatterjee K, Alobaida M, Shipley E, Lip GYH. The Liverpool Heart And bRain Project (L-HARP): Protocol for an Observational Cohort Study of Cardiovascular Risk and Outcomes Following Stroke. Vasc Health Risk Manag. 2022 Apr 26;18:313-318. doi: 10.2147/VHRM.S357829. eCollection 2022.
PubMed 35502192
Study at a glance
From the registry record, last updated by the sponsor on 21 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Liverpool-Heart and BRain Project Stroke Cohort
- ClinicalTrials.gov ID
- NCT05132465
- Acronym / sponsor ID
- L-HARP / UoL001512
- Conditions
- Stroke, Ischemic, Transient Ischemic Attack
- Keywords
- stroke, observational study
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,655 participants (actual)
- Lead sponsor
- University of LiverpoolUniversity, hospital or other
- Study start
- 12 Oct 2021 (actual)
- Primary completion
- 10 Jun 2024 (actual)
- Study completion
- 10 Jun 2024 (actual)
- First posted
- 24 Nov 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
What research question is being addressed?
Can improve the prediction of adverse outcomes be improved for people following a stroke to optimise their treatment and care?
How is it of relevance and importance to patients and public?
Following a stroke, people are at a higher risk of developing certain conditions including heart failure, another stroke and atrial fibrillation, a type of irregular heart rhythm. In the proposed study, the investigators will look at factors which may increase a person's risk of such conditions following stroke. From this, the investigators will determine if risk scores for these conditions can be improved for people post-stroke. This could help doctors decide what treatments are best.
Who would be eligible?
All adults at participating hospitals who have had an ischaemic stroke (where the stroke is caused by loss of blood flow to the brain) or a transient ischaemic attack ('mini-stroke') confirmed by a stroke doctor. All patients will be asked to take part in the study, or their family members may be asked to provide advice on their behalf if the patient is unable to.
Where is the study being conducted?
At participating hospitals in England and Wales.
What will the participants undergo?
At the time of stroke, patients have a lot of information collected about their health, the investigators will copy information from patient's medical records about their health after they agree to take part in the study. Patients or their family members will also be asked to complete some additional brief questionnaires about their quality of life, wellbeing and fatigue. Some questionnaires such as for cognitive function are already collected for patients following a stroke, but where this information has not been collected, it will be collected for the study. The investigators will ask the patients if they can be contacted in 12-months to repeat the questionnaires and information collected about their health.
Detailed description
Study purpose and design.
People with prior stroke are at a high-risk of incident adverse cardiovascular outcomes including heart failure, atrial fibrillation (AF), recurrent stroke and vascular cognitive impairment and dementia. However, there is a need to clarify the underlying risk factors for these outcomes specific to post-stroke populations. Extensive research has been conducted to identify individuals at high-risk of cardiovascular disease through the development of risk prediction models. This has led to the incorporation of risk models for cardiovascular disease into guidelines for clinical practice with an aim to improve patient-centred care and decision-making. Risk factors frequently incorporated in such models include age, male sex, hypertension, cholesterol, smoking, and diabetes mellitus. Although some risk prediction models have examined cardiovascular outcomes such as AF in people post-stroke, further research is needed to refine these models and make recommendations for implementation to clinical practice. Identifying precise risk prediction models for cardiovascular disease and cardiovascular-related complications in people post-stroke is needed to target screening for conditions (such as AF) and develop targeted intervention strategies specific to this population.
Quality assurance plan
Pseudo-anonymised data using the unique, non-identifiable participant ID will be collected in an electronic case report form using Research Electronic Data Capture (REDCap; https://www.project-redcap.org). The data entered in to REDCap for the first 20 patients recruited at each site will be remotely checked for completeness. The data entered onto REDCap will be checked against electronic medical records and paper questionnaires at selected sites.
Data checks
The data fields in REDCap have been set with predefined rules for range or consistency and error messages will display when these rules are violated.
Sample size assessment
As one of the main aims of the study is to examine post-stroke risk prediction models for AF, this will be used to determine the sample size. Post-stroke prevalence of AF has been estimated at approximately 24%. Based on the 24% and with a conservative estimate of 15 cases required per variable in the model, 195 cases would be appropriate for a 13-variable model, which is the maximum number of variables included in previous AF prediction models. Therefore, 815 participants would give approximately 195 patients who develop AF required for the model. The study aims to recruit these participants and 20% extra to account for potential loss to follow-up, resulting in a minimum of 978 participants.
Statistical analysis plan
All data collected will be quantitative. Data will be analysed by members of the research team at the Liverpool Centre for Cardiovascular Science. Cox proportional hazard models adjusted for potential confounding factors will be used to examine associations between risk factors and cardiovascular outcomes and mortality. Risk models identified in previous studies for AF and cardiovascular-related outcomes including cardiovascular disease, physical function, cognitive impairment and dementia, quality-of-life, and all-cause and cardiovascular mortality will be examined in the L-HARP stroke cohort. Receiver operating characteristic curves will be constructed, and Harrell C indexes (i.e. area under the curve) will be estimated as a measure of model performance and compared using the DeLong test.
In addition to traditional epidemiological approaches to risk prediction modelling, machine learning methodologies will also be examined. Machine learning has been shown to produce comparable results to traditional cardiovascular disease risk prediction scores, but with advantages such as examining all available data in an unbiased approach which could lead to the discovery of new relationships among data. As the sample is not very large, traditional machine learning techniques including k-Nearest Neighbours, random forest, and decision tree will be utilised rather than deep learning techniques which are usually applied to very large datasets. A subset of the data will be used for the training of the model and the rest of the data will be used for the evaluation of the model. The model derived from machine learning will be compared to risk prediction models described in previous studies. The accuracy, specificity, sensitivity, positive predictive value and negative predictive value of the models will be compared.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 12 Months
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients from participating hospitals with a recent ischaemic stroke confirmed by stroke physician or transient ischaemic attack confirmed by MRI are eligible unless they are received palliative or end-of-life care. This study aims to be as inclusive as possible with recruitment and provide methods for advice to be sought from a personal consultee (relative/friend/carer) where informed consent is not possible in line with the Mental Capacity Act 2005.
Key inclusion criteria (2 listed)
- ≥18 years old
- Current in-patient at a participating hospital the time of baseline data collection for recent ischaemic stroke confirmed by stroke physician or transient ischaemic attack confirmed by magnetic resonance imaging (MRI)
Key exclusion criteria (2 listed)
- Inability to provide informed consent and no personal consultee available or personal consultee does not think the person would want to participate
- Receiving palliative or end-of-life care
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number of participants with incident stroke, transient ischaemic attack, atrial fibrillation, myocardial infarction and heart failure
Time frame: 12 months
Incident stroke, transient ischaemic attack, atrial fibrillation, myocardial infarction and heart failure
Mortality
Time frame: 12 months
All-cause mortality and mortality from cardiovascular causes
Number of participants with incident cognitive impairment
Time frame: 12 months
Cognitive impairment determined from Montreal Cognitive Assessment (MoCA) test results
Number of participants with incident dementia
Time frame: 12 months
Dementia determined from clinical diagnosis
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Feb 2025.
- Derived from this study: PubMed 35502192Harrison SL, Lane DA, Buckley BJR, Chatterjee K, Alobaida M, Shipley E, Lip GYH. The Liverpool Heart And bRain Project (L-HARP): Protocol for an Observational Cohort Study of Cardiovascular Risk and Outcomes Following Stroke. Vasc Health Risk Manag. 2022 Apr 26;18:313-318. doi: 10.2147/VHRM.S357829. eCollection 2022.
- Individual participant dataSharing planned: No
Related trials for Stroke, Ischemic
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Active, not recruiting
Improving Visual Field Deficits With Noninvasive Brain Stimulation
Visual Field Defect, Peripheral, Stroke
Recruiting
Biomarkers of Paired VNS
Stroke, Ischemic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Stephanie L Harrison, PhD principal investigator
University of Liverpool
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Stroke, Ischemic and Transient Ischemic Attack, run by University of Liverpool at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants with incident stroke, transient ischaemic attack, atrial fibrillation, myocardial infarction and heart failure (time frame: 12 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05132465, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Feb 2025; AzTrials last refreshed its copy on 6 Nov 2026.